

Does the Paleo diet affect an athlete's health and sport performance?

AUTHORS: Barbara Frączek¹, Aleksandra Pięta¹

¹ Department of Sports Medicine and Human Nutrition, Institute of Biomedical Sciences, University School of Physical Education in Kraków, Poland

ABSTRACT: The aim of the study was to assess the impact of an eight-week Paleo diet on the health status (body composition, haematology and biochemistry of blood and urine) and the level of physical capacity (aerobic and anaerobic) of professional handball players. Fifteen athletes were assigned to two groups: 9 in the experimental group (PD) and 6 in the control group (CD). Significant decreases in body mass (BM), body mass index (BMI), and fat mass (FM) as well as an increase in the fat-free mass (FFM) (%) in both groups were observed. There were no significant differences between groups in particular series during the experiment in all haematological and biochemical indicators of blood and urine. Only HDL-C was significantly higher in the last series in the PD compared to the CD (1.63 mmol/l vs. 1.23 mmol/l). In the Wingate test, there were only single intragroup changes, consisting of a significant decrease in the Wt, MAP and Pmean in the experimental group. There were no significant differences between the groups in individual series or intragroup differences during the experiment, determined by the $\dot{V}O_2\text{max}$, $\dot{V}E_{\text{max}}$, $\dot{V}E \cdot \dot{V}CO_2^{-1}$, RER, and the time of the test with a gradually increasing load on a treadmill, except for a significant decrease of maximum tidal volume (TVmax) in the PD. No adverse effect of the Paleo diet on the health status was found. The use of the Paleo diet slightly adversely affects anaerobic capacity and does not affect the level of aerobic capacity.

CITATION: Frączek B, Pięta A. Does the Paleo diet affect an athlete's health and sport performance? *Biol Sport*. 2023;40(4):1125–1139.

Received: 2022-07-17; Reviewed: 2022-09-24; Re-submitted: 2022-12-16 Accepted: 2022-12-16; Published: 2023-02-08.

Corresponding author:

Barbara Frączek

Department of Sports Medicine and Human Nutrition, Institute of Biomedical Sciences, Faculty of Physical Education and Sport, University of Physical Education in Krakow

ORCID:

Barbara Frączek
0000-0002-5673-6135

Aleksandra Pięta
0000-0003-2246-6496

Key words:

Carbohydrate diet
Paleolithic diet
Alternative diet
Exercise capacity
Body composition

INTRODUCTION

Paleolithic nutrition is based on the principles of evolutionary biology with a focus on the low carbohydrate options available to hunter-gatherers. The Paleo diet consists mainly of grass-fed and pasture-raised meats, vegetables, fruits, fungi, roots and nuts, excludes grains, legumes and dairy products, and limits refined sugars, starches, processed foods and oils. The Paleo diet is defined by the avoidance of particular food sources rather than a specific macronutrient distribution [1].

There are many scientific articles that evaluate effects of the Paleo diet (PD) on health status in people with diseases, such as ischemic heart disease [2], blood lipid disorder [3], overweight or obesity [4–5], diabetes [2, 4, 6], and metabolic syndrome [7], and even in healthy, inactive adults [8, 9]. Most, albeit not all, studies suggest that a PD has positive effects on body composition [2–5, 7, 9], insulin sensitivity and/or fasting blood glucose [2, 3, 7, 8], blood lipids [3, 4, 7–9], and blood pressure [4, 7, 8]. Only a few studies have examined the effects of a PD with exercise on cardiorespiratory fitness in healthy or unhealthy adults [5, 6, 9].

On average, the authors estimate the following ratio of macronutrients: 35% energy from fats, 35% from carbohydrates, and 30% from protein (although no specific amount is the goal) [7]. Currently, researchers evaluating the nutritional value of the Paleo diet classify

it as a moderate-carbohydrate diet [10]. There are many studies determining the impact of a diet with very low amounts of carbohydrates (e.g., ketogenic diet; KD) on athletic performance, while there are only several research trials using a moderate carbohydrate diet in a group of athletes [11]. So far, no scientific studies have been carried out to evaluate the use of the Paleo diet among athletes, despite this diet being currently a very fashionable nutrition strategy willingly used by athletes. It should be noted that the relatively small (but sufficient) amount of carbohydrates in the Paleo diet is increasingly used by athletes with the aim of using fat during exercise and saving carbohydrate reserves. That is why we became interested in this subject and decided to start research assessing the use of the Paleo diet in the context of sports. Considering the athletes' willingness to the use of the Paleo diet, we wanted to assess the impact of an eight-week Paleo diet on the health status (body composition, haematology and biochemistry of blood and urine) and the level of physical capacity (aerobic and anaerobic) of professional handball players.

MATERIALS AND METHODS

Characteristics of participants

At the beginning, 22 professional handball players training competitively were invited to take part in the experiment involving the

application of an eight-week nutritional intervention. Twenty-two athletes who competed in a local, 2nd league team in Kraków were recruited. The inclusion criteria in the study group were: age 18–25 years, at least 5 years of participation in competitive sports, undertaking regular physical activity at least 5 times a week for more than one hour per training session, and participation in national and/or international competitions. Five participants dropped out of the experiment in the first research series as they failed to maintain the nutritional regime, regardless of the diet they were to use, despite the high taste preference for the diet or a rational and expressed willingness to take up the diet indicated in the questionnaire. Two athletes ultimately failed to meet the inclusion criterion for undertaking physical activity for all subjects. Finally, 15 athletes completed the full-time study. Based on the analysis of taste preferences and after expressing their willingness to undertake a rational or Paleo diet, the competitors were assigned to two groups differing in the type of diet: 9 in the experimental group and 6 in the control group. At baseline, the two groups did not differ in terms of age [experimental group: 22.00 (21.00; 24.00), control group: 24.5 (23.25; 26.50)] or in anthropometric parameters [body height: 1.86 (1.81; 1.95) cm and 1.85 (1.81; 1.89) cm, respectively, and body mass: 91.36 (87.5; 99.50) kg and 88.4 (84.7; 100.65) kg, respectively].

Dietary intervention

To determine the individual total energy demand (ED), before starting the experiment, the players performed 10-day monitoring of total energy expenditure (on 8 training days and 2 non-training days) using a heart rate monitor (Polar M400/RS400) [12]. Median energy expenditure (EE) in the experimental group was: 4288 (4127; 5000) kcal on training days and 3400 (2900; 3412) kcal on non-training days, and accordingly in the control group: 4096 (3853; 4775) kcal and 3040 (2860; 3646) kcal. There were no statistically significant differences in EE. The ED in both groups was determined considering a sustainable energy balance.

Based on the determined energy demand and the individual needs for nutrients, body mass and food preferences, two nutritional strategies have been developed: the rational diet (control diet; CD), in accordance with the current nutritional recommendations for active people [12, 13], and the Paleo diet (PD) based on the qualitative recommendations of the nutritional model [1]. The PD included grass-fed and pasture-raised meats, vegetables, fruits, fungi, roots and nuts, excluded grains, dairy products and legumes, and limited refined sugars and highly processed foods [1]. The all-day food rations were prepared using the “Aliant. Dietetic Calculator” 4.10.14 (Cambridge Diagnostics, Poland) considering individual assumptions developed by the researcher, considering the isocaloric model of the diet. A different energy supply was used on training/match days (training sessions were held from Monday to Friday, and matches were held on Saturdays) and on a day off training, intended for regeneration. For a rational diet, the following energy share of macronutrients was adopted: 15% protein (no more than 20%,

depending on body mass; BM), 25% fat (no more than 30%, depending on BM) and approximately 55% carbohydrates (no more than 60%, depending on BM) [13, 14], and for the Paleo diet, accordingly, 30% protein (not less than 20%, depending on BM), 40% fat (not less than 35%, depending on BM) and 30% of carbohydrates (no more than 35%, depending on BM) [8]. A total of 840 daily food rations were created: 504 for the subjects in the experimental group and 336 in the control group, 56 for each subject, which were then prepared by the catering company. The diets were used by competitors for 56 days (eight weeks). During the experiment, the athletes did not take any supplements influencing the resting and exercise metabolism.

Experimental design

The research was conducted in accordance with the Declaration of Helsinki and the research methodology was approved by the Bioethical Committee of the Regional Medical Chamber in Kraków (38/KBL/OIL/2017). The participants were informed in detail about the purpose and course of the study and about the possibility to withdraw from participation in the project at any stage without providing a reason. All the subjects read the written information about the research course, especially the nutritional strategy. The participants provided their written consent for voluntary participation in the trial.

Five measurement points (series) were distinguished: 1 – before the start of nutritional intervention or on the first day of the experiment; 2 – after two weeks of nutritional intervention; 3 – after four weeks of nutritional intervention; 4 – after six weeks of nutritional intervention; 5 – after eight weeks of nutritional intervention (Figure 1). Before starting the experiment and after the 2nd, 4th, 6th and 8th week, the body composition was measured using dual energy X-ray absorptiometry (DXA) using the Lunar iDXA instrument. Fat mass (FM) [% and kg], fat free mass (FFM) [% and kg], lean body mass (body mass without adipose tissue and bone minerals: (LBM) [% and kg], bone mineral content (BMC) [g] and bone mineral density (BMD) [g/cm²] were analysed. The content of muscle mass (MM) [% and kg] was calculated using the Kim formula [15].

In order to assess the health effects of the Paleo diet, on the first day of the study, on an empty stomach, and on the first day of the week after weeks 2, 4, 6 and 8, a qualified nurse took blood samples from the veins in the elbow pit to determine haematological and biochemical blood indicators, i.e. peripheral blood counts (haematocrit, haemoglobin concentration, erythrocyte count, platelets, white blood cell count – leukocytes, leukocyte differentiation: lymphocytes, monocytes, basophils, eosinophils, neutrophils), glucose, insulin, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides (TG), creatinine (Cr), urea (U), uric acid (UA), sodium (Na) and potassium (K), calcium (Ca), magnesium (Mg), liver enzymes: ALT (alanine aminotransferase), AST (aspartic aminotransferase), alkaline phosphatase and GGTP (gamma glutamyltransferase), cystatin C, total bilirubin, free fatty acids (FFA) and beta-hydroxybutyrate (b-HB) (Figure 1). On the

1st day of the tests and after the 2nd, 4th, 6th and 8th weeks, the competitors also left samples of early morning urine to assess their health and acidification levels. Total urine tests were performed, i.e., specific gravity, pH, leukocytes, nitrites, protein, glucose, ketones, urobilinogen, bilirubin, blood (erythrocytes/haemoglobin), colour, transparency as well as sodium, potassium, and creatinine levels.

After the blood was drawn, the participants consumed a standardized meal. For each participant of the experiment, a carbohydrate-protein supplement was prepared for consumption (a gainer made of hydrolysed beef protein without milk proteins). Moreover, each of the subjects consumed ad libitum highly mineralized mineral water. Then, the subjects started the exercise test to assess anaerobic capacity. Afterwards, they performed their first anaerobic test – Wingate’s 20-second test for upper limbs. The load was 4.5% of the body mass for the upper limbs (the Monark 834e, Sweden) and 7.5% of the body mass for the lower limbs (the Monark 894e cycle ergometer, Sweden). The software used (MCE 4.2, JBA Staniak, Poland) allowed the following indicators to be registered: total work performed (Wt [kJ], Wt [J · kg⁻¹]), mean anaerobic power (Pmean [W], Pmean [W · kg⁻¹]), maximum anaerobic power (MAP [W], MAP [W · kg⁻¹]) and the time of reaching (t_r [s]) and maintaining (t_m [s]) maximum power. After the first anaerobic test, the players consumed a snack in form of a large apple (approx. 150 kcal) and hydrated themselves with highly mineralized water ad libitum. The competitors rested passively between the tests, and after 45 min the subjects began the Wingate test for lower limbs. On the second day, 1.5 hours before starting the aerobic test the subjects ate a meal planned in the food ration (catering) or its liquid substitute (gainer) and then they performed a laboratory exercise test with a gradually increasing load on a treadmill. To determine the maximum oxygen uptake (VO₂max), using the direct method and the maximum heart rate (HRmax), a laboratory test “until failure” was carried out with a gradually increasing load on a treadmill (h/p/Cosmos Saturn treadmill, Germany). The heart rate (HR) was monitored every

30 seconds during the entire exercise test using the Polar S-410 cardiac monitor (Polar-Electro, Finland). The exercise test was preceded by a 2-minute recording of the initial values of cardiovascular and respiratory indicators on the treadmill (in a standing position). The test started with a 6-minute run at the speed [v] of 7 km/h, the same for all test subjects. Then, running speed was increased by 1.2 km · h⁻¹ every 2 min. The trial was performed until the athlete reported volitional exhaustion and refused to continue the test. Selected indicators of the respiratory and circulatory systems were analysed, including: maximum oxygen uptake (VO₂max [l/min and ml/min/kg]), maximum minute ventilation (VE_{max} [l/min]), maximum tidal volume (TV_{max}), respiratory exchange ratio (RER), respiratory equivalent carbon dioxide (VE · VCO₂⁻¹), heart rate (HR [bpm]). The level of indicators was recorded by the Cortex Metalyzer 3B ergospirometer (Germany) and using the MetaSoft Studio computer program (Germany) (Figure 2).

Statistical analysis

The MS Excel 2010 spreadsheet and the PQStat statistical package, version 1.8.0.338, were used for the statistical analysis of the collected results and their interpretation. The basic characteristics of the examined variables were calculated, i.e.: median (Me), upper quartile (Q1), lower quartile (Q3), delta, arithmetic mean (\bar{x}), standard deviation (SD) and the minimum (min) and maximum (max). The distribution of data was different from normal, so the results of the analysed scales between the groups PD and CD were compared with the non-parametric Mann-Whitney U test in series 1, 2, 3, 4, 5 for components of body composition and haematological parameters in fasting blood and urine biochemistry or in 1, 3, 5 for indicators of aerobic and anaerobic capacity. Intra-group changes in particular series were compared with Friedman’s test and post-hoc Dunn’s test with Bonferroni’s correction. The test probability at the level of $p < 0.05$ was assumed as significant and at the level of $p < 0.01$ was assumed as highly significant.




FIG. 1. Five measurement series.

TABLE 1. Anthropometric parameters, body structure components, haematological and biochemical blood values. Data are reported as median, quartiles and point of change (absolute changes).

| | PD (n = 9) | | | | | | CD (n = 6) | | | | | |
|-----------------------------|-------------------------|-------|--------|---------|---------|----|--------------------------|-------|--------|---------|---------|----|
| | 1 Me (Q1; Q3) | 1-2 | 1-3 | 1-4 | 1-5 | F | 1 Me (Q1; Q3) | 1-2 | 1-3 | 1-4 | 1-5 | F |
| Anthropometric parameters | | | | | | | | | | | | |
| BM [kg] | 91.36 (87.50;99.50) | -1.76 | -0.19* | -4.45** | -2.91** | ** | 88.40 (84.70;100.65) | -0.8 | -0.85 | -2.3 | -2.95** | ** |
| BMI [kg/m ²] | 26.07 (25.75; 27.01) | -0.82 | -0.85* | -0.64** | -0.93** | ** | 25.99 (25.90; 27.90) | -0.28 | -0.31 | -0.49 | -0.5** | ** |
| FM [%] | 22.60 (19.00; 23.30) | -1.6 | -3.0** | -3.20** | -5.0** | ** | 19.15 (18.45; 24.28) | -1.5 | -2.1 | -2.25** | -1.0* | ** |
| FM [kg] | 18.90 (16.15; 21.55) | -1.67 | -2.03 | -2.73** | -3.45** | ** | 16.17 (13.89; 23.41) | -1.41 | -1.9 | -2.3** | -2.11** | ** |
| FFM [%] | 78.39 (73.95; 81.85) | +1.18 | +2.61* | +3.03** | +3.6** | ** | 81.68 (76.77; 82.38) | +1.48 | +2.08 | +2.17** | +1.89* | ** |
| FFM [kg] | 72.93 (67.49; 75.74) | -0.04 | -1.77 | -1.79 | -1.16 | NS | 72.47 (70.84; 77.33) | +0.69 | +0.86 | +0.74 | +0.72 | NS |
| MM [%] | 42.03 (39.00; 42.87) | -0.69 | -1.06* | -0.44* | +0.6 | * | 43.17 (42.00; 43.57) | -2.14 | -1.67 | -0.65 | -1.05 | NS |
| MM [kg] | 38.20 (35.11; 41.13) | -1.71 | -1.73* | -1.43* | -0.75 | * | 38.18 (36.72; 42.41) | -1.04 | -1.5 | -1.18 | -1.0 | * |
| BMC [g] | 3877.00 (3548; 4207) | -54 | -48 | -60 | -52 | * | 3972 (3741; 4229) | +27 | +1 | +11 | -2 | NS |
| BMD [g/cm ²] | 1.42 (1.39; 1.58) | -0.02 | -0.03 | +0.02 | +0.01 | ** | 1.55 (1.44; 1.63) | -0.07 | -0.07 | -0.08 | -0.05 | NS |
| Blood counts | | | | | | | | | | | | |
| HGB [g/dl] | 15.50 (14.80; 16.00) | -0.5 | -0.4 | 0 | -0.4 | NS | 15.50 (14.88; 15.68) | -0.2 | +0.1 | +0.1 | 0 | NS |
| HCT [%] | 45.80 (43.2; 47.60) | -1.3 | -1.0 | -0.7 | -1.0 | NS | 45.60 (43.73; 46.35) | -1.0 | +0.1 | -0.55 | -0.95 | NS |
| Erythrocytes [mln/ μ l] | 5.44 (5.20; 5.53) | -0.13 | -0.11 | -0.15 | -0.29 | NS | 5.22 (5.07; 5.39) | +0.02 | +0.05 | +0.14 | -0.16 | NS |
| MCHC [g/dl] | 34.30 (33.50; 34.30) | 0 | -0.40 | +0.2 | +0.1 | NS | 34.00 (33.93; 34.15) | -0.05 | +0.25 | +0.20 | +0.60 | NS |
| MCH [p/g] | 29.16 (28.60; 29.80) | +0.14 | +0.14 | +0.14 | -0.06 | NS | 29.35 (28.68; 30.40) | +0.40 | +0.45 | +0.25 | +0.30 | NS |
| MCV [fl] | 84.34 (84.10; 87.50) | +0.16 | -0.24 | +0.16 | +0.16 | NS | 86.95 (83.50; 89.95) | +0.01 | +0.25 | -0.75 | -1.40 | * |
| RDW-CW [%] | 12.60 (12.20; 12.90) | -0.1 | -0.1 | -0.2** | -0.2 | * | 12.70 (12.25; 13.15) | +0.05 | +0.2 | -0.1 | -0.3 | NS |
| Leukocytes [tys/ μ l] | 6.79 (6.44; 7.78) | -1.5 | -1.46# | -1.09 | -0.58 | ** | 8.14 (6.03; 8.67) | -1.34 | -1.51# | -1.83 | -1.78 | NS |
| Monocytes [tys/ μ l] | 0.60 (0.50; 0.60) | -0.10 | -0.10# | -0.10# | 0 | ** | 0.65 (0.53; 0.93) | 0 | +0.05# | -0.05# | -0.05 | NS |
| Lymphocytes [tys/ μ l] | 2.80 (2.40; 3.43) | -0.4 | -0.5** | -0.1 | -0.5 | ** | 2.70 (2.25; 3.15) | -0.5 | -0.3 | -0.45 | -0.6 | NS |
| Neutrophils [tys/ μ l] | 3.60 (3.20; 4.00) | -0.9 | -1.1** | -0.8 | -0.8 | ** | 3.95 (3.08; 4.30) | -0.35 | -0.5 | -0.9 | -1.25 | NS |
| Basophils [tys/ μ l] | 0.03 (0.03; 0.05) | 0 | +0.02 | -0.01 | -0.01 | NS | 0.065 (0.04; 0.08) | 0 | -0.005 | -0.005 | -0.005 | NS |
| Eosinophils [tys/ μ l] | 0.11 (0.15; 0.33) | +0.03 | +0.08 | +0.07 | +0.07 | NS | 0.17 (0.13; 0.29) | -0.03 | -0.05 | -0.01 | +0.05 | NS |
| Platelets [tys/ μ l] | 264 (249.00; 277.10) | -2 | -18 | -30 | 0 | * | 259.5 (252.5; 321.25) | +24 | +1 | +6.5 | +5.5 | NS |
| PDW [fl] | 13.50 (12.58; 15.50) | +1.3 | +0.9 | +1.5 | +0.2 | * | 14.55 (13.40; 15.33) | +0.85 | +1.6 | +1.05 | +1.4 | NS |
| P-LCR [%] | 36.00 (32.19; 41.70) | +1.7 | +3.0 | +4.0 | -0.30 | * | 37.60 (34.53; 40.75) | +4.95 | +4.35 | +3.6 | +2.70 | * |
| MPV [fl] | 11.20 (10.78; 12.10) | +0.4 | +0.4 | +0.6 | +0.1 | * | 11.45 (11.10; 11.80) | +0.55 | +0.55* | +0.50 | +0.35 | * |
| PCT [%] | 0.3 (0.3; 0.3) | 0 | 0 | 0 | 0 | NS | 0.3 (0.3; 0.375) | 0 | 0 | 0 | 0 | NS |

TABLE 1. Continue

| | PD (n = 9) | | | | | F | CD (n = 6) | | | | | F |
|--------------------------------------|---------------------------|--------|---------|---------|--------|----|-------------------------|--------|-------|-------|--------|----|
| | 1 Me (Q1; Q3) | 1-2 | 1-3 | 1-4 | 1-5 | | 1 Me (Q1; Q3) | 1-2 | 1-3 | 1-4 | 1-5 | |
| Lipid profile | | | | | | | | | | | | |
| TC [mmol/l] | 3.84 (3.77; 4.31) | +0.03 | +0.53 | +0.33 | +0.27 | NS | 4.65 (4.22; 4.77) | -0.41* | -0.10 | -0.27 | -0.19 | * |
| HDL-C [mmol/l] | 1.39 (1.31; 1.91) | +0.15 | 0 | +0.03 | +0.24# | NS | 1.29 (1.08; 1.64) | -0.10 | -0.11 | -0.09 | -0.06# | NS |
| LDL-C [mmol/l] | 2.18 (2.05; 2.52) | -0.25 | +0.27 | -0.06 | +0.05 | NS | 2.14 (1.81; 2.54) | -0.07 | +0.30 | +0.28 | +0.36 | NS |
| TG [mmol/dl] | 1.02 (0.78; 1.38) | -0.31* | -0.29 | -0.37 | -0.11 | * | 1.36 (1.16; 1.96) | -0.48 | +0.5 | -0.11 | -0.35 | NS |
| Carbohydrates and fat metabolism | | | | | | | | | | | | |
| Glucose [mmol/l] | 5.29 (4.86; 5.44) | -0.6* | -0.45 | -0.69** | -0.13 | ** | 5.10 (5.04; 5.19) | -0.29 | -0.31 | -0.15 | -0.09 | NS |
| Insulin [μIU/ml] | 7.20 (6.69; 8.20) | -1.3 | -1.5 | -1.65 | -0.24 | NS | 6.63 (5.70; 7.51) | -0.48 | +0.86 | +0.87 | -0.58 | NS |
| FFA [mmol/l] | 0.56 (0.24; 0.68) | -0.07 | -0.24 | -0.18 | -0.27 | NS | 0.24 (0.14; 0.39) | +0.32 | +0.21 | +0.04 | +0.05 | NS |
| b-HB [mmol/l] | 0.05 (0.03; 0.06) | +0.14 | +0.05 | +0.09 | +0.03 | NS | 0.04 (0.03; 0.04) | +0.12 | +0.10 | -0.02 | +0.03 | NS |
| Electrolytes | | | | | | | | | | | | |
| Sodium [mmol/l] | 142.00 (141.00; 95.00) | -1 | 0 | -2 | +13* | * | 141.5 (139.50; 142) | -2.5 | -0.5 | -1 | 0 | NS |
| Calcium [mmol/l] | 2.36 (2.29; 2.45) | +0.09 | +0.13** | +0.11* | +0.14* | ** | 2.42 (2.39; 2.47) | +0.06 | +0.10 | +0.02 | -0.01 | NS |
| Magnesium [mmol/l] | 0.83 (0.81; 0.84) | +0.06 | +0.03 | +0.05 | +0.02 | NS | 0.83 (0.81; 0.85) | +0.11* | +0.06 | +0.03 | 0 | ** |
| Potassium [mmol/l] | 4.51 (4.34; 4.79) | 0 | -0.01 | +0.11 | -0.14 | NS | 4.58 (4.36; 4.92) | -0.03 | +0.02 | +0.09 | +0.14 | NS |
| Kidney parameters | | | | | | | | | | | | |
| Creatinine [μmol/l] | 93.00 (81.00; 95.00) | +13 | +12 | +10* | +1 | * | 94.00 (93.25; 94.00) | +6.5 | +7 | +1.5 | +9.5* | ** |
| eGFR [ml/min/1.73m ²] | 88.13 (83.79; 91.00) | -12.32 | -11.71 | -9.94 | -1.09 | * | 85.93 (84.09; 86.19) | -6.9 | -8.36 | -3.53 | -9.63 | * |
| Urea [mmol/l] | 5.00 (4.60; 8.49) | +2.2 | +1.6 | +1.9 | +1.9 | NS | 5.70 (5.53; 6.10) | -0.35 | +0.4 | +0.55 | +1.7 | NS |
| Uric acid [μmol/l] | 320 (310.00; 368.00) | +51 | +18 | +42 | +19 | NS | 303(274.25; 314.50) | +71* | +44 | +36 | +34 | NS |
| Cystatin C [mg/dl] | 0.86 (0.76; 0.86) | -0.08 | -0.08 | -0.02 | +0.07 | * | 0.79 (0.70; 0.89) | +0.04 | +0.07 | +0.03 | +0.10 | ** |
| Urine pH | 6.5 (5; 7) | -1.5 | -1.5 | -1.5 | -1.5 | NS | 5.5 (5; 6.75) | 0 | -0.5 | +0.25 | -0.5 | NS |
| Liver parameters | | | | | | | | | | | | |
| ALT [U/l] | 21.00 (18.00; 32.00) | +5 | +4.7 | +1 | +1 | NS | 25.50 (19.25; 34.75) | -1.6 | -3.7 | -4.2 | -4.9 | NS |
| AST [U/l] | 23.00 (19.00; 28.00) | +1 | +1 | -2.2 | -1.2 | NS | 26.50 (25.25; 27.75) | +1.52 | -1.82 | -4.12 | -3.07 | NS |
| Alkaline Phosphatase [U/l] | 88.00 (63.00; 106.00) | -9 | -12 | -8 | +3 | * | 77.50 (67.50; 90.50) | +4.5 | +4 | -1.5 | 0 | NS |
| GGTP [mmol/l] | 17.00 (11.00; 20.00) | -2 | -4 | -4* | -4 | * | 16.00 (11.75; 20.25) | -2 | -3 | -3 | -2.5 | NS |
| Total bilirubin [μmol/l] | 7.70 (6.10; 8.50) | +1.5 | +2.2 | +2.8 | 0 | NS | 7.40 (5.78; 12.25) | +2.75 | +3.2 | +1.55 | +1.55 | NS |

Abbreviations: PD – Paleo diet; CD – control diet; Me – median; Q1 – upper quartile; Q3 – lower quartile; 1–2; 1–3; 1–4; 1–5 – differences between particular series; F – Friedman's Test; BM – body mass; BMI – body mass index; FM – fat mass; FFM – fat free mass; MM – muscle mass; BMC – body mineral content; BMD – body mass density; HGB – haemoglobin; HCT – hematocrit; MCHC – mean corpuscular hemoglobin concentration; MCH – mean corpuscular haemoglobin; MCV – mean corpuscular volume; RDW-CV – red blood cell distribution with coefficient of variation; PDW – platelet distribution width; P-LCR – platelet-large cell ratio; MPV – mean platelet volume; PCT – procalcitonin; TC – total cholesterol; HDL-C – high-density lipoprotein cholesterol; LDL-C – low-density lipoprotein cholesterol; TG – triglycerides; FFA – free fatty acids; b-HB – beta-hydroxybutyrate; e-GFR – estimated glomerular filtration rate; ALT – alanine aminotransferase; AST – aspartate aminotransferase; GGTP – gamma-glutamyl transferase; italics – changes between 1–5 series; * – test probability at the level of $p < 0.05$ intragroup; ** – $p < 0.01$; # – test probability at the level of $p < 0.05$ intergroup; ## – $p < 0.01$ in U-Mann test.

TABLE 2. Anaerobic and aerobic capacity. Data are reported as median, quartiles and point of change (absolute changes).

| | PD (n = 9) | | | | CD (n = 6) | | | |
|-------------------------------------|----------------------------|--------|-----------------|----|-------------------------|-------|---------------|----|
| | 1 Me (Q1; Q3) | 1-3 | 1-5 | F | 1 Me (Q1; Q3) | 1-3 | 1-5 | F |
| Wingate test on upper limbs | | | | | | | | |
| Wt [kJ] | 10.31 (10.13; 11.20) | +0.26 | <i>-0.42*</i> | * | 10.27 (9.61; 11.00) | +0.27 | -0.21 | NS |
| Wt [J · kg ⁻¹] | 112.00 (107.00; 117.00) | -4 | +4 | NS | 110.00 (104.50; 117.75) | +5 | +7.5 | NS |
| MAP [W] | 597.93 (586.00; 660) | +7.07 | <i>-33.93**</i> | * | 597.50 (560.00; 664.25) | +11.5 | -15.5 | NS |
| MAP [W · kg ⁻¹] | 6.45 (5.96; 6.99) | -0.17 | +0.06 | NS | 6.41 (6.23; 6.75) | +0.43 | +0.44 | NS |
| Pmean [W] | 515.71 (506.00; 560.00) | +12.29 | <i>-20.71*</i> | ** | 513.00 (480; 550) | +14 | -10.5 | NS |
| Pmean [W · kg ⁻¹] | 5.60 (5.30; 5.90) | -0.20 | +0.20 | NS | 5.50 (5.23; 5.85) | +0.25 | +0.35 | NS |
| t _r [s] | 5.14 (5.10; 5.23) | +0.18 | +0.4 | NS | 4.71 (4.30; 5.40) | +0.03 | +0.32 | NS |
| t _{mz} [s] | 3.70 (3.16; 3.75) | +0.32 | -0.07 | NS | 2.52 (2.34; 2.62) | +0.87 | +0.96 | NS |
| Wingate test on lower limbs | | | | | | | | |
| Wt [kJ] | 17.65 (17.27; 19.71) | -1.02 | <i>-1.8**</i> | ** | 17.40 (16.45; 17.83) | -0.05 | -2.53 | NS |
| Wt [J · kg ⁻¹] | 191.21 (181.00; 196.00) | +2.79 | <i>-12.21**</i> | ** | 186.00 (182.25; 191.25) | +5.36 | -5.36 | NS |
| MAP [W] | 1063.00 (1028.00; 1164.15) | -5 | <i>-117**</i> | ** | 1092.50 (954.75; 1141) | -29 | <i>-87.5*</i> | * |
| MAP [W · kg ⁻¹] | 11.47 (10.62; 11.65) | 0 | -0.56 | * | 11.50 (10.58; 12.68) | -0.18 | -0.55 | NS |
| Pmean [W] | 882.00 (864.00; 985.00) | -50 | <i>-90**</i> | ** | 870.00 (822.51; 892.00) | -2.5 | -38.5 | NS |
| Pmean [W · kg ⁻¹] | 9.55 (9.10; 9.80) | +0.15 | -0.65 | * | 9.30 (9.08; 9.60) | +0.27 | -0.11 | NS |
| t _r [s] | 4.08 (3.86; 4.23) | +0.02 | +0.25 | NS | 3.63 (3.25; 4.44) | -0.09 | -0.10 | NS |
| t _m [s] | 3.03 (2.65; 3.73) | -0.13 | -0.28 | NS | 2.52 (2.34; 2.62) | +0.22 | +0.3 | NS |
| Aerobic capacity test | | | | | | | | |
| VO ₂ max [l/min] | 4.40 (3.85; 4.64) | -0.10 | -0.11 | NS | 4.26 (4.09; 4.43) | -0.18 | -0.05 | NS |
| VO ₂ max [ml/kg/min] | 46.00 (42.33; 49.00) | +1 | 0 | NS | 48.00 (43.25; 49.00) | +0.93 | +0.68 | NS |
| VE _{max} [l/min] | 147.60 (143.60; 166.70) | +5.5 | -0.7 | NS | 153.55 (146.28; 162.78) | +3.1 | -0.65 | NS |
| TV _{max} [l] | 2.85 (2.65; 3.38) | 0 | <i>-0.08*</i> | * | 2.69 (2.61; 2.90) | +0.11 | +0.09 | NS |
| RER | 1.10 (1.08; 1.13) | 0 | +0.02 | NS | 1.14 (1.12; 1.17) | +0.03 | +0.01 | NS |
| VE · VCO ₂ ⁻¹ | 29.80 (28.60; 32.80) | -0.70 | -0.80 | NS | 29.70 (29.23; 30.70) | +0.45 | -0.79 | NS |
| HR _{max} [bpm] | 187 (184; 195) | 0 | <i>-3**</i> | ** | 187 (176; 197) | -1 | <i>-4*</i> | * |
| t [min] | 16.50 (15.00; 18.50) | +0.5 | 0 | NS | 17.75 (15.88; 18.88) | +1.25 | +0.5 | NS |
| v [km/h] | 14.86 (14.10; 15.50) | +0.54 | +0.54 | * | 16.05 (14.53; 16.60) | +0.7 | +0.6 | NS |

Abbreviations: PD – Paleo diet; CD – control diet; Me – median; Q1 – upper quartile; Q3 – lower quartile; 1-3; 1-5 – differences between particular series; Wt– total work performed; MAP – maximum anaerobic power; Pmean – mean anaerobic power; t_r– time of reaching maximum power; t_m– time of maintaining maximum power; VO₂max – maximum oxygen uptake; VE_{max} – maximum minute ventilation; TV_{max} – maximum tidal volume; RER – respiratory exchange ratio; VE · VCO₂⁻¹ – respiratory equivalent carbon dioxide; HR_{max} – maximum heart rate; t-time; v – speed; F – Friedman's Test; italics – changes between 1-5 series; * – test probability at the level of $p < 0.05$ intragroup; ** – $p < 0.01$.

single intragroup changes, consisting of a significant decrease in the Wt (kJ), MAP (W) and Pmean (W) in the experimental group. A significant decrease ($p = 0.014$) in the total amount of work performed between the beginning and the end of the intervention (10.31 kJ vs. 9.89 kJ) was observed. Also, in MAP and Pmean significantly lower values were found between the initial and final series: 597.93 W vs. 564.00 W and 515.71 W vs. 495.00 W, respectively (Table 2). In the Wingate test on lower limbs in the PD, post-hoc analysis showed a significant decrease ($p = 0.001$) between the beginning and the end of the intervention in the Wt (17.65 kJ vs. 15.85 kJ). Similarly, the total work performed per kilogram of BM differed significantly ($p = 0.004$) in the PD. During the experiment significantly lower MAP values between the baseline and end series in the PD ($p = 0.003$) (1063.00 W vs. 946.00 W) and in the CD ($p = 0.028$) (1092.00 W vs. 1005.00 W) were observed. A significant decrease ($p = 0.018$) in MAP per kg BM was observed between the mid point and the end of the experiment ($11.47 \text{ W} \cdot \text{kg}^{-1}$ vs. $10.91 \text{ W} \cdot \text{kg}^{-1}$) only in the PD. During the intervention, significant differences ($p = 0.008$) in Pmean with a downward trend ($p = 0.002$) were observed only in the PD. These changes consisted in significantly lower ($p = 0.007$) mean anaerobic power, especially between the beginning and end of the experiment (882.00 W vs. 792.00 W) (Table 2). There were no significant differences between the groups in individual series or intragroup differences during the experiment, determined by the VO_2max (minute and relative to BM), VE_{max} , $\text{VE} \cdot \text{VCO}_2^{-1}$, RER, and the time of the test with a gradually increasing load on a treadmill, except for a significant decrease ($p = 0.018$) of TVmax, between the beginning and the end of the intervention ($p = 0.014$) (2.85 l vs. 2.73 l). HRmax significantly decreased between the initial and final series in the PD ($p = 0.001$) (187 bpm vs. 184 bpm) and CD ($p = 0.014$) (187 bpm vs. 183 bpm) group (Table 2). Tables with the results showing arithmetic means and standard deviation are included in the paper's appendix.

DISCUSSION

There is no research assessing the impact of the Paleo diet on body composition in a group of professional athletes. In our research the eight-week application of the Paleo and control diet had a positive effect on body composition through a decrease in BM, BMI, FM (% and kg) and an increase in FFM% (but not in kg). The beneficial impact of PD on body structure (BM, waist circumference, weight/height ratio and % of FM) applies to various groups: healthy people with a sedentary lifestyle [9], inactive people with planned physical activity (aerobic and resistance training) [4–6] or patients with: ischemic heart disease [2], lipid profile disorders [3], overweight and obesity [4, 5], diabetes [5, 6], or metabolic syndrome [7]. The applied Paleo diets were characterized by consumption ad libitum, while with the normoenergetic nature of PD, the changes showed mainly no body mass reduction effect [8] but were often related to the improvement of some metabolic indicators [7, 8]. There are only a few studies in which the normoenergetic model of the Paleo diet

was used [7, 8]. It is not unequivocally determined whether applying the energy deficit or the distribution of macronutrients is the cause of the changes in body weight. In the study by Michalczyk et al. [11], FM of basketball players did not depend on the amount of fat, but the amount and quality of carbohydrates consumed in the Carbo-L (a 7-day carbohydrate loading protocol) or low-carbohydrate diet and the increase in FM occurred only as a result of loading with carbohydrates. Conversely, a meta-analysis of 94 studies on low-carbohydrate diets found that weight loss following a low-carbohydrate diet was associated with a reduction in energy consumption and dietary duration, but not with a reduction in dietary carbohydrates [16]. Similarly, we observed a significant reduction in BM and FM in both the experimental and control groups, although in the first weeks the reduction effect was more visible in the PD group. Moreover, maintaining FFM during fat reduction was observed in athletes and inactive people using a lower carbohydrate (LCD) and ketogenic diet (VLCD-KD) [17–18]. In contrast, McSwiney et al. [18] found that after a short-term ketogenic diet in endurance-trained males there was a decrease in both FM and FFM. It seems that the PD (as well as the KD and LCD), when it provides an adequate supply of calories and is accompanied by properly selected training, should result in the maintenance of FFM, especially in a short time of use.

An important factor in the discussion on the necessity of following alternative diets is their impact on health. Scientists dealing with alternative strategies mention a number of possible positive consequences of adopting various nutritional strategies, e.g., the ketogenic diet, training with high or low availability of carbohydrates [19, 20]. It is recommended to implement dietary strategies to increase antioxidant potential of the diet (e.g. fresh fruits, vegetables, sprouts as well as seeds) [21]. In addition, reduction in consumption of refined foods, including carbohydrates, may be critical in preventing or treating metabolic-related cognitive deficits [22]. We found that the eight-week use of the PD does not cause significant, unfavourable changes in health. We observed no effect on lipid profile, except for higher HDL cholesterol concentration after eight weeks of using the Paleo diet. This trend is in line with analyses of the use of the Paleo diet in inactive people. In a meta-analysis Ghaedi et al. [23] found that PD reduces the concentration of total cholesterol (TC), LDL cholesterol and triglycerides (TG) and increases the concentration of HDL cholesterol. Similar results were obtained by Manheimer et al. [24], observing favourable changes in HDL concentration. According to Noakes et al. [25], changes in the blood lipid profile depend on the dietary fat content. A positive effect on the lipid profile in the group of athletes on the LCD and KD was also observed and according to the authors it may have been caused by the predominance of polyunsaturated fatty acids [11, 26]. Moreover, the Paleo diet provided significantly more pro-inflammatory saturated fatty acids (SFAs) and cholesterol. Unfavourable changes in lipid profile that result from applying the high fat diets are more pronounced after diets high in SFAs. Higher consumption of SFA and cholesterol could cause hypercholesterolaemia in 20 ultra-endurance athletes [27] and low-carbohydrate diets

promote atherosclerotic changes in athletes [28]. The Paleo diet is not a risk that stimulates the development of cardiovascular diseases resulting from disturbances in the lipid profile [23]. Therefore, it can be concluded that with a high supply of polyunsaturated fatty acids (PUFAs) even a high content of SFAs and cholesterol in the diet did not have a negative effect on the lipid profile. In our research, no changes in all assessed indicators of metabolism of carbohydrates and fat were found, which remained within the reference values throughout the entire experiment in the PD and CD, as also occurred in the group of basketball players on an LCD [11]. A meta-analysis by Jamka et al. [29] showed that the Paleo diet may improve glucose tolerance, reduce insulin secretion, and increase insulin sensitivity in people with impaired glucose metabolism, as well as other healthy diets (the Mediterranean diet, diabetes diet, and a diet recommended by the Dutch Health Council). Other studies with limited carbohydrate intake showed a decrease in blood insulin concentration at rest or during exercise [30, 31] or no effect [26, 32–34]. Scientific studies show that lipolysis and fat oxidation increased as insulin levels decreased [25]. Elevated ketone levels are necessary to induce decreased insulin production and thus increase fat utilization [35]. Perhaps that is why in our research no decrease in blood insulin was observed. In numerous studies using the KD, the level of ketosis considered desirable was also not observed [36]. In turn, the studies by Zajac et al. [26] showed that the KD in cyclists caused a fourfold increase in the concentration of b-HB before exercise and a twofold increase in resting FFA concentration in plasma. Our analysis did not show that use of the PD increased the oxidation of fatty acids, and the level of ketones in the urine was minimal or undetectable in the course of the experiment.

There was no effect of the 8-week PD on blood counts, electrolytes and kidney and liver function indicators, which remained within the reference intervals throughout the intervention. In the research by Urbain et al. [30], no effect of the 6-week ketogenic diet on the level of total bilirubin, AST, or creatine was found, but a significant decrease in alkaline phosphatase, and increases in ALT, concentration of urea and uric acid were observed at the end of the experiment in the group of 42 healthy adults. Uric acid concentration may serve as one biomarker of keto-adaptation in the kidneys [37]. Researchers have found that serum uric acid remains above baseline levels even after 12 weeks on the KD [38]. In our research, no changes in uric acid concentration in the PD were found. On the other hand, long-term use of an acidic diet in combination with exercise leads to an initial impairment of renal function [39]. In the analysis of the effect of the 6-week ketogenic diet on healthy adults, no changes in creatinine levels were found.

Numerous studies have been conducted investigating the potential ergogenic effects of low-carbohydrate diets. The LCD accelerate the feeling of fatigue and reduce concentration by reducing the effectiveness of training [28]. On the other hand, many studies have shown that LCD (most often with higher protein content, above 30%) through weight loss, and in some cases resulting in an increase in

FFM, especially in weight-category sports, may contribute to the improvement of exercise capacity [17, 18, 34, 40]. Especially in short-term resistance efforts, it is recommended to eat more carbohydrates, which is based on evidence supporting the importance of glycogen as both an energy “fuel” and a regulator of skeletal muscle adaptive responses during exercise [41]. On the other hand, there is insufficient evidence that carbohydrates are required for mammalian target of rapamycin complex-1 (mTORC-1) signalling during muscle protein synthesis [42], especially when dietary protein intake is adequate [43]. Thus, adaptive changes resulting from the use of LCD may, on the one hand, improve the aerobic capacity, but on the other hand may reduce the possibility of using exogenous carbohydrates, which in turn may contribute to the lack of improvement in efficiency, and may even worsen the exercise capacity, during more intense physical efforts [19, 44]. An undoubted advantage of the Paleo diet is the sufficient carbohydrate content (in the context of glycogen availability), but the disadvantage may be the lack of ketosis occurring in the KD – enabling the use of fatty acids in energy processes. However, as previously demonstrated in some sports, for instance team sports, it is not necessary to consume high carbohydrates in the daily diet due to the lower training volume and the shorter duration of the competition [11]. In this case, the Paleo diet may be the correct choice. It has been reported that supervised exercise in combination with the Paleo diet (PDEX) influenced the maintenance of LBM in men and increased cardiovascular capacity in patients with diabetes [4]. Higher $VO_2\max$ values have also been observed in healthy, inactive, non-overweight people after PD. However, these changes would be the result of training rather than diet [9]. In the research of Popp et al. [45], which compared the PD in combination with physical activity to a “MyPlate” diet that included both aerobic training and resistance training, a greater improvement in exercise capacity was observed with a rational diet (“MyPlate”). Kang et al. [36] identified a few independent studies in which no effect of a KD on $VO_2\max$ was demonstrated [32–34, 46, 47], while in two research papers, the authors reported a decrease in $VO_2\max$ in l/min [30, 48], and an increase in $VO_2\max$ [26]. A significant increase in $VO_2\max$ was observed in a group of cyclists using KD compared to a mixed diet [26]. The authors explain the improvement in $VO_2\max$ (ml/kg/min) accompanying the use of the KD as a consequence of a decrease in BM and FM [26]. Our research did not show an effect of the use of the PD on the maximum oxygen uptake or other indicators of aerobic capacity, either in absolute or relative values, despite the BM reduction. So, it was found in our research that the normoenergetic PD model can be successfully used by athletes without adversely affecting aerobic capacity. Analysing the indicators of anaerobic capacity, we observed a decrease in total amount of work performed in the PD, the maximum and mean power in absolute values in both the Wingate test and in relative $Wt [J \cdot kg^{-1}]$ only in the Wingate test on lower limbs. However, the time to achieve and maintain MAP in the PD did not decrease significantly. Kang et al. [36] reported seven studies assessing the effect of the KD on anaerobic capacity. In a few,

there was no effect on muscle strength and power [17, 49, 50]. In studies by Rhyu and Cho [40] in both diet groups, KD and NKD (non-ketogenic diet), with a distribution of macronutrients similar to the PD, the diet resulted in a decrease in MAP and Pmean of taekwondo athletes. Research suggests that low-carbohydrate, high-fat or ketogenic diets may be useful in weight loss, most often without compromising strength or power [36]. It cannot be clearly stated that the Paleo diet adversely affects anaerobic capacity in athletes. A longer follow-up and larger sample size are recommended in future clinical trials of the Paleo diet used on athletes.

LIMITATIONS

The factor limiting the research was the size of the research group. The high cost of catering to meet individual energy needs, representing a high level of sports and the specific products of the Paleo diet (meat, fish, seafood, eggs, nuts, fruit, and vegetables) made it impossible to include more athletes in the experiment (22 people were planned and 15 athletes completed the study). Preparing meals with the assumption of maintaining balanced energy especially with high energy demand and the specific composition of the Paleo diet eliminated the possibility of methodological errors. The presented results of the pilot studies are the nucleus of the planned research process on a larger scale.

CONCLUSIONS

1. Eight-week intervention of the Paleo diet resulted in a decrease in body mass, body mass index and the amount of fat mass, which should be considered a beneficial effect of the diet in the context of the body structure of handball players.

2. There was no adverse effect of the Paleo diet on the health status of research participants, assessed with the following indicators: peripheral blood count, lipid profile, carbohydrate and fat metabolism, concentration of selected electrolytes, kidney and liver function and urine assessment. The use of the Paleo diet significantly increased the concentration of HDL cholesterol in the group following the Paleo diet compared to the rational diet, even with a significantly higher content of SFA and cholesterol in the Paleo diet (3 and 2 times higher than the norm, respectively).

3. Eight-week use of the Paleo diet slightly adversely affects anaerobic capacity, reducing some of the assessment indicators, i.e., total work performed, mean and maximum anaerobic power, and does not affect the level of aerobic capacity of handball players.

4. The Paleo diet can be used by representatives of disciplines that do not require high availability of carbohydrates (e.g., team sports) and players planning to obtain optimal body composition in a short period of time.

Acknowledged

Funding for the research project included funds from scientific research for the development of young scientists and participants in doctoral studies (106/MN/INB/2017) and statutory research/research potential (113/BS/INB/2016) at the University of Physical Education in Krakow.

Conflict of interest statement

The authors declare no conflict of interest.

REFERENCES

- Konner M, Eaton SB. Paleolithic nutrition: Twenty-five years later. *Nutr. Clin. Pract.* 2010; 25:594–602.
- Lindeberg S, Jonsson T, Granfeldt Y, Borgstrand E, Soffman J, Sjostrom K, Ahren BA. Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischemic heart disease. *Diabetologia* 2007; 50:1795–1807.
- Pastore RL, Brooks JT, Carbone JW. Paleolithic nutrition improves plasma lipid concentrations of hypercholesterolemic adults to a greater extent than traditional heart-healthy dietary recommendations. *Nutr. Res.* 2015; 35:474–479.
- Otten J, Stomby A, Waling M, Isaksson A, Tellström A, Lundin-Olsson L, Brage S, Ryberg M, Svensson M, Olsson T. Benefits of a Paleolithic diet with and without supervised exercise on fat mass, insulin sensitivity, and glycemic control: A randomized controlled trial in individuals with type 2 diabetes. *Diabetes Metab. Res. Rev.* 2017; 33:e2828.
- Otten J, Stomby A, Waling M, Isaksson A, Söderström I, Ryberg M, Svensson M, Hauksson J, Olsson T. A heterogeneous response of liver and skeletal muscle fat to the combination of a Paleolithic diet and exercise in obese individuals with type 2 diabetes: A randomized controlled trial. *Diabetes* 2018; 61:1548–1559.
- Stomby A, Otten J, Ryberg M, Nyberg L, Olsson T, Boraxbekk CJ. A Paleolithic Diet with and without Combined Aerobic and Resistance Exercise Increases Functional Brain Responses and Hippocampal Volume in Subjects with Type 2 Diabetes. *Front. Aging Neurosci.* 2017; 9:391.
- Boers I, Muskiet FA, Berkelaar E, Schut E, Penders R, Hoenderdos K, Wichers HJ, Jong MC. Favourable effects of consuming a Palaeolithic-type diet on characteristics of the metabolic syndrome: A randomized controlled pilot-study. *Lipids Health Dis.* 2014; 13:160.
- Frassetto LA, Schloetter M, Mietus-Snyder M, Morris RC, Sebastian A. Metabolic and physiologic improvements from consuming a Paleolithic, hunter-gatherer type diet. *Eur. J. Clin. Nutr.* 2009; 63:947–955.
- Smith MM, Trexler ET, Sommer AJ, Starkoff BE, Devor ST. Unrestricted Paleolithic diet is associated with unfavorable changes to blood lipids in healthy subjects. *Int. J. Exerc. Sci.* 2014; 7:128–139.
- Frączek B, Pięta A, Burda A, Mazur-Kurach P, Tyrła F. Paleolithic Diet—Effect on the Health Status and Performance of Athletes? *Nutrients* 2021; 13:1019.
- Michalczyk M, Zajac A, Mikolajec K, Zydek G, Langfort J. No Modification in Blood Lipoprotein Concentration but Changes in Body Composition After 4 Weeks of Low Carbohydrate Diet (LCD) Followed by 7 Days of Carbohydrate Loading in Basketball Players. *J. Hum. Kinet.* 2018; 65:125–137.
- Frączek B, Grzelak A, Klimek A. Analysis of Daily Energy Expenditure of Elite Athletes in Relation to Their Sport, the Measurement Method and Energy

- Requirement Norms. *Journal of Human Kinetics*. 2019; 70:81–92.
13. Dietary Reference Values for nutrients. Summary report. European Food Safety Authority (EFSA). 2017:15121,92.
 14. Kersick ChM, Wilborn CD, Roberts MD, Smith-Ryan A, Kleiner SM, Jäger R, Collins R, Cooke M, Davis JN, Galvan E, Greenwood M, Lowery LM, Wildman R, Antonio J, Kreider RB. ISSN exercise & sports nutrition review update: research & recommendations. *J Int Soc Sports Nutr*. 2018; 15(1):38.
 15. Kim J, Wang Z, Heymsfield S, Baumgartner R, Gallagher D. Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. *American Journal of Clinical Nutrition*. 2002; 76:378–83.
 16. Bravata DM, Sanders L, Huang J, Krumholz HM, Olkin I, Gardner CD.: Efficacy and safety of low-carbohydrate diets: a systematic review. *JAMA*, 2003; 289(14):1837–50.
 17. Paoli A, Grimaldi K, D'Agostino D, Cenci L, Moro T, Bianco A, Palma A. Ketogenic diet does not affect strength performance in elite artistic gymnasts. *J. Int. Soc. Sports Nutr*. 2012; 9(1):34.
 18. McSwiney FT, Ben Fusco B, McCabe L et al. Changes in body composition and substrate utilization after a short-term ketogenic diet in endurance-trained males. *Biol Sport*. 2021; 38(1):145–152.
 19. Jeukendrup AE. Periodized nutrition for athletes. *Sports Med*. 2017; 47:51–63.
 20. Dearlove DJ, Harrison OK, Hodson L, Jefferson A, Clarke K, Cox PJ. The Effect of Blood Ketone Concentration and Exercise Intensity on Exogenous Ketone Oxidation Rates in Athletes. *Med. Sci. Sports Exerc*. 2021; 53(3):505–516.
 21. Frączek B, Gacek M, Pięta A, Tyrała F, Mazur-Kurach P, Karpecka E. Dietary mistakes of Polish athletes in relation to the frequency of consuming foods recommended in the Swiss food pyramid for active people. *Rocz Panstw Zakl Hig*. 2020; 71(1):97–104.
 22. Karpecka E, Frączek B. Macronutrients and water – do they matter in the context of cognitive performance in athletes? *Balt J Health Phys Activ*. 2020; 12(3):114–135.
 23. Ghaedi E, Mohammadi M, Mohammadi H, Ramezani-Jolfaie N, Malekzadeh J, Hosseinzadeh M, Salehi-Abargouei A. Effects of a paleolithic Diet on Cardiovascular Disease Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Adv. Nutr.*, 2019; 10(4):634–646
 24. Manheimer EW, van Zuuren EJ, Fedorowicz Z, Pijl H. Paleolithic nutrition for metabolic syndrome: Systematic review and meta-analysis. *Am. J. Clin. Nutr.*, 2015; 102(4):922–932.
 25. Noakes M, Foster PR, Keogh JB, James AP, Mamo JC, Clifton PM. Comparison of isocaloric very low carbohydrate/high saturated fat and high carbohydrate/low saturated fat diets on body composition and cardiovascular risk. *Nutr Metab (Lond)*. 2006; 3(1):7.
 26. Zając A, Poprzęcki S, Maszczyk A, Czuba M, Michalczyk M, Zydek G. The effects of a ketogenic diet on exercise metabolism and physical performance in off-road cyclists. *Nutrients*. 2014; 6(7):2493–2508.
 27. Creighton BC, Hyde PN, Maresh CM, Kraemer WJ, Phinney SD, Volek JS. Paradox of hypercholesterolaemia in highly trained, keto-adapted athletes. *BMJ Open Sport Exerc. Med*. 2018; 4(1):e000429.
 28. Moctezuma-Velázquez C, García-Juárez I, Soto-Solís R, Hernández-Cortés J, Aldo Torre. Nutritional assessment and treatment of patients with liver cirrhosis. *Nutrition*. 2013; 29(11–12):1279–85.
 29. Jamka M, Kulczynski B, Juruć A, Gramza-Michałowska A, Stokes CS, Walkowiak J. The Effect of the paleolithic Diet vs. Healthy Diets on Glucose and Insulin Homeostasis: A systematic review and meta-analysis of randomized controlled trials. *J. Clin. Med*. 2020; 9:296.
 30. Urbain P, Strom L, Morawski L, Wehrle A, Deibert P, Bertz H. Impact of a 6-week non-energy-restricted ketogenic diet on physical fitness, body composition and biochemical parameters in healthy adults. *Nutr Metab (Lond)*. 2017; 14(1):17.
 31. Durkalec-Michalski K, Nowaczyk PM, Siedzik K. Effect of a four-week ketogenic diet on exercise metabolism in CrossFit-trained athletes. *J Int Soc Sports Nutr*. 2019; 16(1):16.
 32. Phinney SD, Bistrian BR, Evans WJ, Gervino E, Blackburn GL. The human metabolic response to chronic ketosis without caloric restriction: Preservation of submaximal exercise capability with reduced carbohydrate oxidation. *Metabolism*. 1983; 32(8):769–776.
 33. Helge JW, Richter EA, Kiens B. Interaction of training and diet on metabolism and endurance during exercise in man. *J Physiol.*, 1996; 492(1):293–306.
 34. Volek JS, Freidenreich DJ, Saenz C, Kunces LJ, Creighton BC, Bartley JM, Davitt PM, Munoz CX, Anderson JM, Maresh CM, Lee EC, Schuenke MD, Aerni G, Kraemer WJ, Phinney SD. Metabolic characteristics of keto-adapted ultra-endurance runners. *Metabolism*. 2016; 65(3):100–110.
 35. Evans M, McSwiney FT, Brady AJ, Egan B. No Benefit of Ingestion of a Ketone Monoester Supplement on 10-km Running Performance. *Med. Sci. Sports Exerc*. 2019; 51(12):2506–2515.
 36. Kang J, Ratamess NA, Faigenbaum AD, Bush J. Ergogenic Properties of Ketogenic Diets in Normal-Weight Individuals: A Systematic Review. *Journal of the American College of Nutrition* 2020; 39(3):1–11.
 37. Sherrier M, Li H. The impact of keto-adaptation on exercise performance and the role of metabolic-regulating cytokines. *Am J Clin Nutr*. 2019; 110(3):562–573.
 38. Mohorko N, Cernelic-Bizjak M, Poklar-Vatovec T, Grom G, Kenig S, Petelin A, Jenko-Praznikar Z. Weight loss, improved physical performance, cognitive function, eating behavior, and metabolic profile in a 12-week ketogenic diet in obese adults. *Nutr Res.*, 2019; 62:64–77.
 39. Baranauskas M, Jablonskiene V, Abaravičius JA, Samsoniene L, Stukas R. Dietary Acid-Base Balance in High-Performance Athletes; *Int. J. Environ. Res. Public Health*. 2020; 17(15):5332.
 40. Rhyu HS, Cho SY. The effect of weight loss by ketogenic diet on the body composition, performance-related physical fitness factors and cytokines of Taekwondo athletes. *J Exerc Rehabil*. 2014; 10(5):326–31.
 41. Phinney SD. Ketogenic diets and physical performance. *Nutrition & Metabolism*. 2004; 17(1):1–2.
 42. Escobar KA, Van Dusseldorp TA, Kersick CM. Carbohydrate intake and resistance-based exercise: are current recommendations reflective of actual need? *Br J Nutr*. 2016; 116(12):2053–65.
 43. Phillips SM. A Brief Review of Critical Processes in Exercise-Induced Muscular Hypertrophy. *Sports Med*. 2014; 44(1):71–77.
 44. Close GL, Hamilton L, Philp A, Burke LM, Morton JP. New strategies in sport nutrition to increase exercise performance. *Free Radic Biol Med*. 2016; 98:144–58.
 45. Popp CJ, Bohan Brown MM, Bridges WC, Jesch ED. The Effectiveness of MyPlate and paleolithic-based Diet Recommendations, both with and without Exercise, on Aerobic Fitness, Muscular Strength and Anaerobic Power in Young Women: A randomized Clinical Trial. *Int J Exerc Sci*. 2018;11(2):921–933.
 46. Zinn C, Wood M, Williden M, Chatterton S, Maunder E: Ketogenic diet benefits body composition and well-being but not performance in a pilot case study of New Zealand endurance athletes. *J. Int. Soc. Sports Nutr*. 2017; 14, 22–31.
 47. Kephart WC, Pledge CD, Roberson PA, Mumford PW, Romero MA, Mobley CB, Martin JS, Young KC, Lowery RP, Wilson JM, Huggins KW, Roberts MD.

- The three-month effects of a ketogenic diet on body composition, blood parameters, and performance metrics in crossfit trainees: A pilot study. *Sports (Basel)*. 2018; 6(1):1.
48. Fleming J, Sharman MJ, Avery NG, Love DM, Gomez AL, Scheett TP, Kraemer WJ, Volek JS. Endurance capacity and high-intensity exercise performance responses to a high fat diet. *Int J Sport Nutr Exerc Metab*. 2003; 13(4):466–478.
49. Greene DA, Varley BJ, Hartwig TB, Chapman P, Rigney M. A low-carbohydrate ketogenic diet reduces body mass without compromising performance in powerlifting and Olympic weight-lifting athletes. *J Strength Cond Res*. 2018; 32(12):3373–3382.
50. Heatherly AJ, Killen LG, Smith AF, Waldman HS, Seltmann CL, Hollingsworth A, O'Neal EK. Effects of Ad libitum Low-Carbohydrate High-Fat Dieting in Middle-Age Male Runners. *Med. Sci. Sports Exerc*. 2018; 50(3):570–579.

SUPPLEMENTARY TABLE 1. Anthropometric parameters, body structure components, hematological and biochemical blood values. Data are reported as arithmetic mean, standard deviation and point of change (absolute changes).

| | PD (n = 9) | | | | | | CD (n = 6) | | | | | |
|----------------------------------|--------------------|--------|---------|---------|---------|----|--------------------|--------|--------|---------|---------|----|
| | 1 $\bar{x} \pm SD$ | 1-2 | 1-3 | 1-4 | 1-5 | F | 1 $\bar{x} \pm SD$ | 1-2 | 1-3 | 1-4 | 1-5 | F |
| Anthropometric parameters | | | | | | | | | | | | |
| BM [kg] | 93.52 ± 9.74 | -2.46 | -3.47* | -4.47** | -4.65** | ** | 92.47 ± 13.10 | -0.67 | -1.05 | -1.69 | -2.45** | ** |
| BMI [kg/m ²] | 26.73 ± 1.79 | -0.71 | -1.00* | -1.30** | -1.33** | ** | 27.16 ± 2.28 | -0.22 | -0.34 | -0.52 | -0.75** | ** |
| FM [%] | 23.25 ± 5.82 | -1.73 | -2.64** | -2.97** | -3.92** | ** | 21.68 ± 5.45 | -1.73 | -2.60 | -3.31** | -3.53* | ** |
| FM [kg] | 20.70 ± 7.04 | -1.71 | -2.77 | -3.25** | -4.09** | ** | 19.83 ± 8.04 | -1.58 | -2.42 | -3.05** | -3.36** | ** |
| FFM [%] | 77.28 ± 5.82 | +1.61 | +2.63* | +2.76** | +3.69** | ** | 79.24 ± 5.26 | +1.70 | +2.56 | +3.20** | +3.40* | ** |
| FFM [kg] | 72.06 ± 7.47 | -0.41 | -0.45 | -0.94 | -0.25 | NS | 72.63 ± 5.78 | +0.94 | +1.41 | +1.37 | +0.93 | NS |
| MM [%] | 41.10 ± 3.13 | -0.88 | -0.39* | -0.18* | +0.63 | * | 42.35 ± 1.70 | -0.88 | -0.75 | +0.16 | -0.16 | NS |
| MM [kg] | 38.37 ± 4.38 | -1.81 | -1.73* | -1.90* | -1.33 | * | 38.96 ± 4.03 | -1.13 | -0.89 | -1.21 | +3.39 | * |
| BMC [g] | 3877.29 ± 496.30 | -14.56 | -9.89 | -4.48 | -13.69 | * | 3997.00 ± 397.05 | +3.33 | -2.17 | -10.33 | -15.83 | NS |
| BMD [g/cm ²] | 1.47 ± 0.12 | -0.03 | -0.04 | 0 | -0.01 | ** | 1.54 ± 0.11 | -0.04 | -0.05 | -0.04 | -0.03 | NS |
| Blood counts | | | | | | | | | | | | |
| HGB [g/dl] | 15.31 ± 1.13 | -0.34 | -0.22 | -0.12 | -0.19 | NS | 15.28 ± 0.69 | -0.21 | +0.19 | +0.17 | -0.18 | NS |
| HCT [%] | 45.00 ± 3.21 | -1.23 | -0.89 | -0.88 | -1.24 | NS | 42.90 ± 1.89 | -0.70 | +0.50 | +0.15 | -1.32 | NS |
| Erythrocytes [mln/ μ l] | 5.25 ± 0.46 | -0.14 | -0.08 | -0.07 | -0.08 | NS | 5.19 ± 0.33 | -0.11 | -0.02 | 0 | -0.12 | NS |
| MCHC [g/dl] | 34.03 ± 0.57 | +0.14 | +0.20 | +0.37 | +0.56 | NS | 34.03 ± 0.44 | +0.07 | +0.04 | +0.27 | +0.60 | NS |
| MCH [pg] | 29.24 ± 0.81 | +0.08 | -0.01 | +0.12 | -0.05 | NS | 29.48 ± 0.94 | +0.25 | +0.45 | +0.35 | +0.37 | NS |
| MCV [fl] | 85.95 ± 2.53 | -0.11 | -0.45 | -0.64 | -1.23 | NS | 86.63 ± 3.44 | +0.57 | +1.20 | +0.42 | -0.51 | * |
| RDW-CW [%] | 12.67 ± 0.42 | -0.17 | -0.21 | -0.34** | -0.24 | * | 12.70 ± 0.44 | +0.02 | +0.02 | +0.12 | -0.18 | NS |
| Leukocytes [tys/ μ l] | 7.33 ± 1.43 | -1.58 | -1.96# | -1.20 | -1.00 | ** | 7.74 ± 1.81 | -0.91 | -0.49# | -1.22 | -0.88 | NS |
| Monocytes [tys/ μ l] | 0.63 ± 0.16 | -0.06 | -0.15# | -0.13# | -0.01 | ** | 0.73 ± 0.24 | -0.08 | -0.03# | -0.10# | -0.03 | NS |
| Lymphocytes [tys/ μ l] | 2.95 ± 0.72 | -0.61 | -0.67** | -0.38 | -0.47 | ** | 2.77 ± 0.63 | -0.42 | -0.10 | -0.10 | -0.20 | NS |
| Neutrophils [tys/ μ l] | 3.49 ± 0.86 | -0.81 | -1.10** | -0.62 | -0.48 | ** | 3.92 ± 1.59 | -0.30 | -0.24 | -0.90 | -0.60 | NS |
| Basophils [tys/ μ l] | 0.05 ± 0.03 | -0.01 | 0 | -0.01 | -0.01 | NS | 0.07 ± 0.03 | -0.01 | -0.01 | -0.01 | -0.01 | NS |
| Eosinophils [tys/ μ l] | 0.24 ± 0.11 | -0.06 | -0.05 | -0.01 | -0.01 | NS | 0.23 ± 0.16 | -0.06 | -0.08 | -0.04 | +0.01 | NS |
| Platelets [tys/ μ l] | 266.23 ± 31.93 | -5.45 | -21.00 | -27.12 | -6.23 | * | 290.33 ± 62.64 | -7.00 | -20.83 | -6.16 | -22.83 | NS |
| PDW [fl] | 14.14 ± 2.00 | +0.05 | +0.63 | +0.99 | -0.13 | * | 14.48 ± 1.17 | +0.84 | +1.25 | +1.19 | +1.32 | NS |
| P-LCR [%] | 35.64 ± 6.82 | +1.69 | +3.19 | +3.72 | -0.05 | * | 37.65 ± 4.09 | +3.43 | +3.85 | +3.23 | +2.65 | * |
| MPV [fl] | 11.24 ± 0.85 | +0.29 | +0.4 | +0.49 | +0.07 | * | 11.47 ± 0.48 | +0.40 | +0.50* | +0.44 | +0.38 | * |
| PCT [%] | 0.30 ± 0 | 0 | 0 | -0.01 | 0 | NS | 0.35 ± 0.08 | -0.02 | -0.03 | -0.06 | -0.05 | NS |
| Lipid profile | | | | | | | | | | | | |
| TC [mmol/l] | 4.20 ± 0.76 | -0.20 | +0.30 | +0.05 | -0.07 | NS | 4.55 ± 0.63 | -0.59* | -0.19 | -0.23 | -0.42 | * |
| HDL-C [mmol/l] | 1.49 ± 0.34 | +0.20 | -0.01 | +0.02 | +0.25# | NS | 1.45 ± 0.48 | -0.10 | -0.08 | -0.17 | -0.11# | NS |
| LDL-C [mmol/l] | 2.19 ± 0.61 | -0.26 | +0.20 | +0.13 | -0.01 | NS | 2.32 ± 0.72 | -0.28 | +0.12 | +0.09 | +0.01 | NS |
| TG [mmol/dl] | 1.17 ± 0.46 | -0.34* | -0.34 | -0.26 | -0.19 | * | 1.70 ± 0.85 | -0.43 | -0.47 | -0.32 | -0.68 | NS |
| Carbohydrates and fat metabolism | | | | | | | | | | | | |
| Glucose [mmol/l] | 5.20 ± 0.32 | -0.59* | -0.31 | -0.51** | -0.15 | ** | 5.14 ± 0.18 | -0.37 | -0.28 | -0.21 | -0.17 | NS |
| Insulin [μ lU/ml] | 8.24 ± 3.35 | -1.1 | -1.55 | -0.45 | +0.01 | NS | 7.59 ± 2.85 | +0.11 | +1.72 | +0.16 | -1.62 | NS |
| FFA [mmol/l] | 0.50 ± 0.22 | -0.01 | -0.08 | +0.07 | -0.14 | NS | 0.34 ± 0.26 | +0.25 | +0.16 | +0.04 | 0 | NS |
| b-HB [mmol/l] | 0.05 ± 0.02 | +0.21 | +0.12 | +0.14 | +0.09 | NS | 0.08 ± 0.11 | +0.18 | +0.06 | +0.01 | +0.03 | NS |

SUPPLEMENTARY TABLE 1. Continue

| | PD (n = 9) | | | | | | CD (n = 6) | | | | | |
|------------------------------------|--------------------|-------|---------|--------|--------|----|--------------------|---------|--------|--------|---------|----|
| | 1 $\bar{x} \pm SD$ | 1-2 | 1-3 | 1-4 | 1-5 | F | 1 $\bar{x} \pm SD$ | 1-2 | 1-3 | 1-4 | 1-5 | F |
| Electrolytes | | | | | | | | | | | | |
| Sodium [mmol/l] | 142.65 \pm 2.02 | -2.15 | -1.35 | -0.65 | -0.21* | * | 140.80 \pm 1.34 | -1.47 | +0.2 | +0.5 | +0.70 | NS |
| Calcium [mmol/l] | 2.36 \pm 0.08 | +0.10 | +0.15** | +0.12* | +0.11* | ** | 2.44 \pm 0.07 | +0.03 | +0.07 | 0 | +0.02 | NS |
| Magnesium [mmol/l] | 0.83 \pm 0.03 | +0.05 | +0.05 | +0.04 | +0.02 | NS | 0.83 \pm 0.04 | +0.08* | +0.07 | +0.03 | -0.01 | ** |
| Potassium [mmol/l] | 4.60 \pm 0.28 | -0.09 | -0.11 | +0.03 | -0.07 | NS | 4.63 \pm 0.29 | -0.05 | -0.01 | -0.03 | +0.06 | NS |
| Kidney parameters | | | | | | | | | | | | |
| Creatinine [μ mol/l] | 90.26 \pm 9.72 | +8.07 | +9.96 | +9.41* | +2.96 | * | 93.33 \pm 1.60 | +11.00 | +9.67 | +4.84 | +10.67* | ** |
| eGFR [ml/min/1.73 m ²] | 86.40 \pm 5.15 | -6.59 | -7.52 | -6.62 | -2.62 | * | 85.92 \pm 2.61 | -9.67 | -9.03 | -4.42 | -9.94 | * |
| Urea [mmol/l] | 6.15 \pm 1.90 | +1.08 | +0.63 | +1.36 | +0.38 | NS | 5.90 \pm 1.22 | -0.17 | -0.20 | +0.82 | +1.07 | NS |
| Uric acid [μ mol/l] | 330.90 \pm 47.06 | +38.7 | +34.46 | +35.9 | +5.21 | NS | 297.85 \pm 49.16 | +81.15* | +57.65 | +58.95 | +39.32 | NS |
| Cystatin C [mg/dl] | 0.82 \pm 0.10 | -0.04 | -0.02 | 0 | +0.06 | * | 0.79 \pm 0.10 | +0.04 | +0.07 | +0.04 | +0.09 | ** |
| Urine pH | 6.10 \pm 0.92 | -0.66 | -0.82 | -0.6 | -0.77 | NS | 5.83 \pm 0.90 | -0.08 | -0.50 | -0.08 | -0.41 | NS |
| Liver parameters | | | | | | | | | | | | |
| ALT [U/l] | 25.37 \pm 8.49 | -1.53 | +2.82 | -1.65 | -0.53 | NS | 29.17 \pm 12.69 | -1.79 | +0.35 | -4.30 | -3.79 | NS |
| AST [U/l] | 25.38 \pm 8.90 | -1.04 | -0.42 | -3.15 | -3.18 | NS | 25.33 \pm 6.07 | +2.69 | -0.65 | -2.95 | -1.90 | NS |
| Alkaline Phosphatase [U/l] | 84.65 \pm 22.06 | -8.54 | -6.76 | -4.43 | +0.57 | * | 80.33 \pm 15.65 | +0.34 | +2.5 | -2.16 | +1.00 | NS |
| GGTP [mmol/l] | 20.27 \pm 14.15 | -5.05 | -7.05 | -7.16* | -5.94 | * | 16.83 \pm 6.41 | -2.66 | -2.16 | -2.00 | -3.83 | NS |
| Total bilirubin [μ mol/l] | 7.64 \pm 2.13 | +2.03 | +2.38 | +2.39 | +0.88 | NS | 9.81 \pm 5.61 | +1.09 | +0.92 | -1.03 | -0.76 | NS |

Abbreviations: PD – Paleo diet; CD – control diet; \bar{x} – arithmetic mean; SD – standard deviation; 1-2; 1-3; 1-4; 1-5 – differences between particular series; F – Friedman's Test; BM – body mass; BMI – body mass index; FM – fat mass; FFM – fat free mass; MM – muscle mass; BMC – body mineral content; BMD – body mass density; HGB – haemoglobin; HCT – hematocrit; MCHC – mean corpuscular hemoglobin concentration; MCH – mean corpuscular haemoglobin; MCV – mean corpuscular volume; RDW-CV – red blood cell distribution with coefficient of variation; PDW – platelet distribution width; P-LCR – platelet-large cell ratio; MPV – mean platelet volume; PCT – procalcitonin; TC – total cholesterol; HDL-C – high-density lipoprotein cholesterol; LDL-C – low-density lipoprotein cholesterol; TG – triglycerides; FFA – free fatty acids; b-HB – beta-hydroxybutyrate; e-GFR – estimated glomerular filtration rate; ALT – alanine aminotransferase; AST – aspartate aminotransferase; GGTP – gamma-glutamyl transferase; italics-changes between 1-5 series; * – test probability at the level of $p < 0.05$ intragroup; ** – $p < 0.01$; # – test probability at the level of $p < 0.05$ intergroup; ## – $p < 0.01$ in U-Mann test.

SUPPLEMENTARY TABLE 2. Anaerobic and aerobic capacity. Data are reported as arithmetic mean, standard deviation and point of change (absolute changes).

| | PD (n = 9) | | | | CD (n = 6) | | | |
|-------------------------------------|--------------------|--------|------------------|----|--------------------|--------|----------------|----|
| | 1 $\bar{x} \pm SD$ | 1-3 | 1-5 | F | 1 $\bar{x} \pm SD$ | 1-3 | 1-5 | F |
| Wingate test on upper limbs | | | | | | | | |
| Wt [kJ] | 10.36 ± 1.04 | -0.48 | <i>-1.01*</i> | * | 10.25 ± 1.02 | +0.28 | -0.01 | NS |
| Wt [J · kg ⁻¹] | 111.85 ± 10.55 | -2.07 | <i>-5.07</i> | NS | 111.33 ± 7.87 | +5.67 | +4.84 | NS |
| MAP [W] | 595.77 ± 71.92 | -29.90 | <i>-59.10**</i> | * | 601.17 ± 67.63 | +13.33 | -0.017 | NS |
| MAP [W · kg ⁻¹] | 6.41 ± 0.71 | -0.12 | <i>-0.30</i> | NS | 6.52 ± 0.42 | +0.29 | +0.26 | NS |
| Pmean [W] | 517.97 ± 52.03 | -24.41 | <i>-50.19*</i> | ** | 512.33 ± 51.15 | +14.17 | 0 | NS |
| Pmean [W · kg ⁻¹] | 5.59 ± 0.56 | -0.10 | <i>-0.26</i> | NS | 5.57 ± 0.40 | +0.26 | +0.23 | NS |
| t _r [s] | 5.26 ± 0.82 | +0.20 | +0.18 | NS | 4.86 ± 0.72 | -0.13 | +0.17 | NS |
| t _m [s] | 4.11 ± 1.43 | -0.17 | <i>-0.36</i> | NS | 3.12 ± 0.74 | +0.49 | +0.60 | NS |
| Wingate test on lower limbs | | | | | | | | |
| Wt [kJ] | 17.90 ± 1.99 | -1.01 | <i>-2.15**</i> | ** | 17.31 ± 2.24 | -0.04 | -0.88 | NS |
| Wt [J · kg ⁻¹] | 189.91 ± 10.52 | -1.69 | <i>-10.47**</i> | ** | 187.33 ± 12.67 | +3.63 | -1.95 | NS |
| MAP [W] | 1062.35 ± 114.55 | -30.68 | <i>-132.91**</i> | ** | 1077.83 ± 176.07 | -37.71 | <i>-38.85*</i> | * |
| MAP [W · kg ⁻¹] | 11.25 ± 0.57 | +0.17 | <i>-0.65</i> | * | 11.61 ± 1.11 | -0.12 | +0.08 | NS |
| Pmean [W] | 895.35 ± 99.56 | -50.70 | <i>-83.81**</i> | ** | 865.33 ± 112.09 | -2.00 | -40.08 | NS |
| Pmean [W · kg ⁻¹] | 9.49 ± 0.53 | -0.09 | <i>-0.28</i> | * | 9.37 ± 0.64 | +0.19 | -0.02 | NS |
| t _r [s] | 4.04 ± 0.56 | +0.01 | +0.65 | NS | 3.72 ± 0.84 | -0.21 | +0.03 | NS |
| t _m [s] | 3.81 ± 2.21 | -1.03 | +0.13 | NS | 2.48 ± 0.52 | +0.26 | +0.16 | NS |
| Aerobic capacity test | | | | | | | | |
| VO ₂ max [l/min] | 4.31 ± 0.56 | -0.01 | -0.14 | NS | 4.22 ± 0.26 | -0.01 | -0.02 | NS |
| VO ₂ max [ml/kg/min] | 45.70 ± 4.05 | +2.3 | +1.63 | NS | 45.83 ± 4.37 | +1.48 | +1.90 | NS |
| VE _{max} [l/min] | 149.93 ± 15.90 | -5.63 | -9.06 | NS | 154.10 ± 8.69 | +2.76 | -5.31 | NS |
| TV _{max} [l] | 2.99 ± 0.49 | -0.04 | <i>-0.13*</i> | * | 2.91 ± 0.51 | -0.08 | -0.04 | NS |
| RER | 1.11 ± 0.04 | -0.01 | -0.01 | NS | 1.14 ± 0.04 | +0.01 | -0.01 | NS |
| VE · VCO ₂ ⁻¹ | 30.12 ± 2.41 | -0.76 | -0.83 | NS | 30.37 ± 2.08 | +0.47 | -0.52 | NS |
| HR _{max} [bpm] | 188.59 ± 7.96 | -2.14 | <i>-6.81**</i> | ** | 186.00 ± 11.56 | -0.23 | <i>-5.98*</i> | * |
| t [min] | 16.78 ± 2.02 | +0.89 | +0.44 | NS | 17.00 ± 2.39 | +0.80 | +0.25 | NS |
| v [km/h] | 14.70 ± 1.15 | +0.43 | +0.66 | * | 15.45 ± 1.37 | +0.79 | +0.52 | NS |

Abbreviations: PD – Paleo diet; CD – control diet; \bar{x} – arithmetic mean; SD – standard deviation; 1-3; 1-5 – differences between particular series; Wt – total work performed; MAP – maximum anaerobic power; Pmean – mean anaerobic power; t_r – the time of reaching maximum power; t_m – time of maintaining maximum power; VO₂max – maximum oxygen uptake; VE_{max} – maximum minute ventilation; TV_{max} – maximum tidal volume; RER – respiratory exchange ratio; VE · VCO₂⁻¹ – respiratory equivalent carbon dioxide; HR_{max} – maximum heart rate; t-time; v – speed; F – Friedman’s Test; *italics* – changes between 1-5 series; * – test probability at the level of $p < 0.05$ intragroup; ** – $p < 0.01$.